DarrenFeldmanMD

Genitourinary Oncology, Hematologic Oncology

Associate Attending, Memorial Sloan Kettering Cancer Center and Associate Professor of Medicine, Weill Cornell Medical College

Request Appointment

Overview of Dr. Feldman

Dr. Darren Feldman is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 15 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in testicular neoplasms, kidney cancer, and urologic oncology

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(424) 329-4357

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Chief Residency, Internal Medicine, 2004 - 2005
NYU Grossman School of MedicineInternship, Internal Medicine, 2001 - 2004
University of Maryland School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2004 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Jul 01
Completed
Phase 2
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls Start of enrollment: 2011 Oct 11
Active, not recruiting
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 2
Germ Cell Tumor and Testicular Tumor DNA Registry Start of enrollment: 2014 Jan 01
Recruiting
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression Start of enrollment: 2015 Feb 26
Completed
Phase 2
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer Start of enrollment: 2022 Feb 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.
Fady Baky, Nicole Liso, Brandon Williams, Andrea Knezevic, Samuel A Funt
Clinical Genitourinary Cancer. 2024-12-01
Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review.
Valentina Tateo, Zachary J Thompson, Scott M Gilbert, Victoria K Cortessis, Siamak Daneshmand
European Urology. 2024-11-13
1 citations
Long-term Outcomes of Regressed or "Burnt Out" Primary Testicular Germ Cell Tumors.
Fady J Baky, Nicole Liso, Brandon Williams, Victor E Reuter, Satish K Tickoo
Urology. 2024-11-01

Journal Articles

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Lectures

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for in...
2019 ASCO Annual Meeting - 6/1/2019
Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patien...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAMMarch 22nd, 2023
Monrol Is Partnering with Telix Pharmaceuticals, Supplying Lutetium Nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study at MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON TrialMay 10th, 2022
Cabozantinib Improves Quality-Adjusted Survival in Advanced RCCOctober 23rd, 2020
Join now to see all